Using in vitro cell line models, we show that upregulating or downregulating ezrin decreased or increased, respectively, the sensitivity of breast cancer cells to doxorubicin (DOX) and docetaxel (DTX) treatment. This evidence concerns the gene EZR and breast cancer.